PD-L1-negative tumors (including possibly false-negative findings due to tumor heterogeneity, or cases with discordant expression patterns between the primary tumor and metastasis) may respond to ICI-based treatment, or tumors that test positive may not respond. This evidence concerns the gene CD274 and neoplasm.